左心超声造影指标LVESV、LVEF、LVEDV与慢性心力衰竭患者心功能分级的关系及对抗心力衰竭疗效的评估价值

doi:10.3969/j.issn.1006-5725.2026.10.010

Abstract

Abstract:

Objective To explore the relationship between left heart contrast echocardiography indexes， including left ventricular end - systolic volume （LVESV）， left ventricular ejection fraction （LVEF）， and left ventricular end-diastolic volume （LVEDV）， and the grading of cardiac function， as well as their evaluation value for the anti - heart failure effect in patients with chronic heart failure （CHF）. Methods A total of 102 patients with CHF were recruited between May 2021 and May 2025. All patients underwent routine ultrasound examination and left-heart contrast echocardiography. The quality of apical images and the detection of special structures obtained by the two examination methods were compared. Based on the cardiac function grading of the New York Heart Association （NYHA）， the patients were classified into three groups： Grade IV （n = 27）， Grade III （n = 40）， and Grade II （n = 35）. The LVESV， LVEF， and LVEDV measured by routine ultrasound and left - heart contrast echocardiography in these three groups were compared. The relationship between cardiac function grading and LVESV， LVEF， and LVEDV measured by left - heart contrast echocardiography was analyzed using the Spearman coefficient. After 3 months of anti-heart failure treatment， the CHF patients underwent left - heart contrast echocardiography again. According to the treatment efficacy， they were divided into an ineffective group （n = 23） and an effective group （n = 79）. The difference values of LVESV， LVEF， and LVEDV （ΔLVESV， ΔLVEF， ΔLVEDV） before and after treatment measured by left-heart contrast echocardiography in the two groups were compared. The evaluation value of left - heart contrast echocardiography in assessing the anti-heart failure effect was analyzed using receiver operating characteristic （ROC） curves. Results The quality of apical images obtained through left heart contrast echocardiography was superior to that obtained via routine ultrasound （P < 0.05）. The detection rates of apical thrombosis， ventricular aneurysm， and trabecular hyperplasia by left heart contrast echocardiography were 8.82%， 9.80%， and 14.71% respectively， which were higher than those by routine ultrasound （1.96%， 3.00%， 5.88%； P < 0.05）. The LVESV and LVEDV measured by left heart contrast echocardiography were higher than those measured by routine ultrasound， while the LVEF was lower than that measured by routine ultrasound （P < 0.05）. There were significant differences in LVESV， LVEF， and LVEDV measured by routine ultrasound and left heart contrast echocardiography among patients with different cardiac function grading （P < 0.05）. In the grade IV group， grade III group， and grade II group， LVESV and LVEDV gradually decreased， while LVEF gradually increased （P < 0.05）. Spearman analysis indicated that the cardiac function grading of patients with CHF was negatively correlated with LVEF and positively correlated with LVESV and LVEDV measured by left heart contrast echocardiography （P < 0.05）. After 3 months of treatment， the changes in LVESV （ΔLVESV）， LVEF （ΔLVEF）， and LVEDV （ΔLVEDV） in the effective group were higher than those in the ineffective group （P < 0.05）. ROC curve analysis showed that the area under the curve （AUC） values of ΔLVESV， ΔLVEF， and ΔLVEDV for evaluating the anti-heart failure effect were 0.720， 0.976， and 0.696 respectively （P < 0.05）. Conclusions Left heart contrast echocardiography can enhance the quality of apical images and elevate the detection rates of special structures in patients with CHF. The echocardiographic indexes （LVESV， LVEF， LVEDV） are closely associated with cardiac function grading， and ΔLVEF exhibits the best evaluation efficiency for the anti-heart failure effect. This study offers a basis for the accurate grading and individualized treatment of CHF by comparing left ventricular contrast echocardiography with routine ultrasound and analyzing the difference values of core indexes.

Key words: heart failure, routine ultrasound, left heart contrast echocardiography, diagnostic value, evaluation of curative effect

CLC Number:

R541.6

Lihong LUO,Xianbao KUANG,Hongli GU,Zhen LI. The relationship between left heart contrast echocardiography indexes （LVESV， LVEF， LVEDV） and grading of cardiac function and their evaluation value for anti-heart failure effect in patients with chronic heart failure[J]. The Journal of Practical Medicine, 2026, 42(10): 1762-1769.

Figures/Tables 5

Fig.1

Tab.1

Tab.2

Tab.3

Tab.4

References 27

[1]	莫乔莹，朱芳一，祝存奎，等. 基于GNRI评分构建慢性心力衰竭患者营养不良风险的列线图模型［J］. 实用医学杂志， 2025， 41（5）：691-698. doi： 10.3969/j.issn.1006-5725.2025.05.011 . doi: 10.3969/j.issn.1006-5725.2025.05.011
[2]	ZHANG L， ONO Y， QIAO Q， et al. Trends in heart failure prevalence in Japan 2014-2019： A report from healthcare administration databases［J］. ESC Heart Fail， 2023， 10（3）：1996-2009. doi： 10.1002/ehf2.14321 . doi: 10.1002/ehf2.14321
[3]	NAGUEH S F， SANBORN D Y， OH J K， et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis： An Update From the American Society of Echocardiography［J］. J Am Soc Echocardiogr， 2025， 38（7）：537-569. doi： 10.1016/j.echo.2025.03.011 . doi: 10.1016/j.echo.2025.03.011
[4]	BECHER H， ALHUMAID W， WINDRAM J， et al. Contrast Echocardiography in Heart Failure： Update 2023［J］. Curr Heart Fail Rep， 2024， 21（2）：63-72. doi： 10.1007/s11897-024-00647-z . doi: 10.1007/s11897-024-00647-z
[5]	ZEB I， UQAILY R， GONUGUNTLA K， et al. Multimodality assessment of high- vs. low-gradient aortic stenosis using echocardiography and cardiac CT［J］. J Cardiovasc Comput Tomogr， 2023， 17（6）：421-428. doi： 10.1016/j.jcct.2023.09.002 . doi: 10.1016/j.jcct.2023.09.002
[6]	CHRISTA M， MÜNTZE J， LENGENFELDER B， et al. Contrast-enhanced ultrasound for non-invasive differential diagnosis of unclear left atrial mass［J］. Int J Cardiovasc Imaging， 2023， 39（11）：2173-2174. doi： 10.1007/s10554-023-02926-7 . doi: 10.1007/s10554-023-02926-7
[7]	ANSARI U， JANSSEN S， BAUMANN S， et al. Sparse 3D contrast-enhanced whole-heart imaging for coronary artery evaluation［J］. Herz， 2023， 48（1）：55-63. doi： 10.1007/s00059-021-05091-6 . doi: 10.1007/s00059-021-05091-6
[8]	中华医学会心血管病学分会，中国医师协会心血管内科医师分会，中国医师协会心力衰竭专业委员会，等. 中国心力衰竭诊断和治疗指南2024［J］. 中华心血管病杂志， 2024， 52（3）：235-275. doi： 10.3760/cma.j.cn112148-20231101-00405 . doi: 10.3760/cma.j.cn112148-20231101-00405
[9]	朱天刚，靳文英，张梅，等. 心脏超声增强剂临床应用规范专家共识［J］. 中华医学超声杂志（电子版）， 2019， 16（10）：731-734. doi： 10.3877/cma.j.issn.1672-6448.2019.10.004 . doi: 10.3877/cma.j.issn.1672-6448.2019.10.004
[10]	SCHOU M， PETRIE M C， BORLAUG B A， et al. Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction： The STEP-HFpEF Program［J］. J Am Coll Cardiol， 2024， 84（3）：247-257. doi： 10.1016/j.jacc.2024.04.038 . doi: 10.1016/j.jacc.2024.04.038
[11]	LI T， JIANG Y L， KANG J， et al. Prevalence and risk factors of frailty in older patients with chronic heart failure： a systematic review and meta-analysis［J］. Aging Clin Exp Res， 2023， 35（12）：2861-2871. doi： 10.1007/s40520-023-02587-5 . doi: 10.1007/s40520-023-02587-5
[12]	SAVARESE G， BECHER P M， LUND L H， et al. Global burden of heart failure： a comprehensive and updated review of epidemiology［J］. Cardiovasc Res， 2023， 118（17）：3272-3287. doi： 10.1093/cvr/cvac013 . doi: 10.1093/cvr/cvac013
[13]	OBOKATA M， SORIMACHI H， HARADA T， et al. Epidemiology， Pathophysiology， Diagnosis， and Therapy of Heart Failure With Preserved Ejection Fraction in Japan［J］. J Card Fail， 2023， 29（3）：375-388. doi： 10.1016/j.cardfail.2022.09.018 . doi: 10.1016/j.cardfail.2022.09.018
[14]	WU B， YANG Y， ZHAO P. Application of Routine Echocardiography Combined with Contrast-Enhanced Echocardiography in the Diagnosis of Endomyocardial Fibrosis［J］. Discov Med， 2023， 35（179）：1052-1063. doi： 10.24976/Discov.Med.202335179.101 . doi: 10.24976/Discov.Med.202335179.101
[15]	ZHANG M， CHEN X， YANG F， et al. Evaluation of Left Ventricular Mass in Different Cardiac Geometry Using Three-Dimensional Contrast-Enhanced Echocardiography［J］. Int Heart J， 2023， 64（5）：885-893. doi： 10.1536/ihj.22-663 . doi: 10.1536/ihj.22-663
[16]	LEE K C， LIU S， CALLAHAN P， et al. Routine Use of Contrast on Admission Transthoracic Echocardiography for Heart Failure Reduces the Rate of Repeat Echocardiography during Index Admission［J］. J Am Soc Echocardiogr， 2021， 34（12）：1253-1261. doi： 10.1016/j.echo.2021.07.008 . doi: 10.1016/j.echo.2021.07.008
[17]	GUI H Y， LIU S W， ZHU D F. Interaction between the left ventricular ejection fraction and left ventricular strain and its relationship with coronary stenosis［J］. World J Clin Cases， 2023， 11（10）：2246-2253. doi： 10.12998/wjcc.v11.i10.2246 . doi: 10.12998/wjcc.v11.i10.2246
[18]	CHIORESCU R M， LAZAR R D， RUDA A， et al. Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction［J］. Int J Mol Sci， 2023， 25（1）：440. doi： 10.3390/ijms25010440 . doi: 10.3390/ijms25010440
[19]	SCHMIDT A F， FINAN C， VAN SETTEN J， et al. A Mendelian randomization analysis of cardiac MRI measurements as surrogate outcomes for heart failure and atrial fibrillation［J］. Commun Med （Lond）， 2025， 5（1）：130. doi： 10.1038/s43856-025-00855-1 . doi: 10.1038/s43856-025-00855-1
[20]	ZHANG Y， LI S Y， LU T T， et al. Volume and function changes of left atrium and left ventricle in patients with ejection fraction preserved heart failure measured by a three dimensional dynamic heart model［J］. Int J Cardiovasc Imaging， 2024， 40（3）：509-516. doi： 10.1007/s10554-023-03018-2 . doi: 10.1007/s10554-023-03018-2
[21]	METRA M， TOMASONI D， ADAMO M， et al. Worsening of chronic heart failure： Definition， epidemiology， management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology［J］. Eur J Heart Fail， 2023， 25（6）：776-791. doi： 10.1002/ejhf.2874 . doi: 10.1002/ejhf.2874
[22]	ZHANG X， WANG N， FU P， et al. Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating β-Hydroxybutyrate-activated Citrate Synthase［J］. J Cardiovasc Pharmacol， 2023， 82（5）：375-388. doi： 10.1097/FJC.0000000000001474 . doi: 10.1097/FJC.0000000000001474
[23]	YANG H R， XU X D， SHAIKH A S， et al. Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients： A Meta-Analysis［J］. Ann Pharmacother， 2023， 57（8）：907-917. doi： 10.1177/10600280221140575 . doi: 10.1177/10600280221140575
[24]	CHATUR S， BELDHUIS I E， CLAGGETT B L， et al. Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m² ［J］. JACC Heart Fail， 2024， 12（10）：1692-1703. doi： 10.1016/j.jchf.2024.03.014 . doi: 10.1016/j.jchf.2024.03.014
[25]	HUANG C W， YU A S， ZHOU H， et al. Comparative Effectiveness of Bisoprolol， Carvedilol， and Metoprolol Succinate in Patients with Heart Failure and CKD［J］. Clin J Am Soc Nephrol， 2025， 20（1）：136-138. doi： 10.2215/CJN.0000000000000562 . doi: 10.2215/CJN.0000000000000562
[26]	ELSHAHAT A， ABDELAZIZ A， MANSOUR A， et al. Eplerenone vs Spironolactone and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction： A Meta-Analysis［J］. Mayo Clin Proc， 2025， 100（3）：572-576. doi： 10.1016/j.mayocp.2024.11.009 . doi: 10.1016/j.mayocp.2024.11.009
[27]	CHATUR S， VADUGANATHAN M， CLAGGETT B L， et al. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function［J］. J Am Coll Cardiol， 2023， 82（19）：1854-1863. doi： 10.1016/j.jacc.2023.08.026 . doi: 10.1016/j.jacc.2023.08.026

指标	常规超声	左心超声造影	Z/χ² /t值	P值
心尖部图像质量			6.912	< 0.001
1分	14（13.73）	0（0.00）
2分	24（23.53）	2（1.96）
3分	28（27.45）	14（13.73）
4分	20（19.60）	47（46.07）
5分	16（15.69）	39（38.24）
特殊结构检出
心尖血栓	2（1.96）	9（8.82）	4.708	0.030
室壁瘤	3（2.94）	10（9.80）	3.954	0.047
肌小梁过度	6（5.88）	15（14.71）	4.300	0.038
心尖肥厚	1（0.98）	5（4.90）	2.747	0.097
左心功能指标
LVESV（x ± s）/mL	51.13 ± 12.24	54.56 ± 14.59	5.304	< 0.001
LVEF（x ± s）/%	46.89 ± 6.25	45.75 ± 5.26	2.775	0.007
LVEDV（x ± s）/mL	95.18 ± 13.96	98.98 ± 18.30	4.590	< 0.001

组别	例数	常规超声LVESV/mL	造影LVESV/mL	常规超声LVEF/%	造影LVEF/%	常规超声LVEDV/mL	造影LVEDV/mL
Ⅳ级组	27	64.70 ± 8.29^*#	67.67 ± 10.46^*#	41.66 ± 4.86^*#	41.48 ± 2.98^*#	110.78 ± 9.67^*#	115.26 ± 13.40^*#
Ⅲ级组	40	51.33 ± 8.49^*	55.08 ± 11.98^*	45.98 ± 4.76^*	44.98 ± 3.76^*	94.63 ± 9.63^*	99.05 ± 15.50^*
Ⅱ级组	35	40.43 ± 6.73	43.86 ± 11.40	51.89 ± 4.85	49.91 ± 5.11	83.77 ± 8.60	86.34 ± 14.40
F值		72.420	33.339	35.550	33.315	64.410	29.904
P值		< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001

组别	例数	ΔLVESV/mL	ΔLVEF/%	ΔLVEDV/mL
有效组	79	9.38 ± 2.86	6.03 ± 1.38	7.73 ± 2.46
无效组	23	7.41 ± 1.98	3.57 ± 0.73	6.18 ± 1.70
t值		3.100	8.219	2.824
P值		0.003	< 0.001	0.006

指标	截断值	AUC	95%CI	P值	敏感度/%	特异度/%
ΔLVESV	8.66 mL	0.720	0.611 ～ 0.828	0.001	57.00	82.61
ΔLVEF	4.51%	0.976	0.927 ～ 1.000	< 0.001	100.00	95.65
ΔLVEDV	6.90 mL	0.696	0.580 ～ 0.811	0.004	69.62	65.22

The relationship between left heart contrast echocardiography indexes （LVESV， LVEF， LVEDV） and grading of cardiac function and their evaluation value for anti-heart failure effect in patients with chronic heart failure

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 27

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Guoqiu WANG,Liyong GE,Anning ZENG,Qinyu YANG,Wei LI. Predictive value of combined pulmonary artery pulsatility index and myocardial microcirculation indicators for major adverse cardiovascular events in elderly patients with chronic heart failure with reduced ejection fraction [J]. The Journal of Practical Medicine, 2026, 42(8): 1341-1346.
[2]	Cuixiao MIAO,Kaiting CHEN,Xiaoqing ZHANG,Mi TAN,Xueqin DONG,Yanrong AN,Hui ZHU. The levels of miR-155， miR-31-5p， Aasprosin and GSK-3β predict the risk of osteoporosis in patients with type 2 diabetes [J]. The Journal of Practical Medicine, 2026, 42(8): 1347-1353.
[3]	Gangqiang XU,Zhaosuo HU,Long WANG,Runlin YUAN,Xin CAI,Zhengxu CHEN. The application value of serum osmolality， N-terminal pro-brain natriuretic peptide， and homocysteine in the early diagnosis of acute heart failure in patients with coronary heart disease and hypertension [J]. The Journal of Practical Medicine, 2026, 42(6): 1018-1023.
[4]	Fengren LIU,Pengcheng LI,Wen ZHANG,Feng LI. The application of serum IL⁃7， LDH/ALB and sCD14⁃ST in the diagnosis and disease assessment of COPD combined with PI [J]. The Journal of Practical Medicine, 2026, 42(2): 236-248.
[5]	Lunlun LI,Linlin YANG,Lijuan WANG. Analysis of the relationship between the levels of serum AFABP， PARP1， GRP78 and IGFBP-7 in patients with chronic heart failure and their clinical classification and prognosis [J]. The Journal of Practical Medicine, 2026, 42(10): 1752-1761.
[6]	Lin CHEN,Baochuan WU,Shaojun WU,Yi WANG,Yibei FU,Xiaoli LIU,Rong GU. Clinical efficacy of vericiguat in combination with "Quadruple Therapy" for patients with heart failure and reduced ejection fraction in real⁃world settings [J]. The Journal of Practical Medicine, 2025, 41(9): 1379-1386.
[7]	Chunmei MA,Zhikang WU,Ke CHEN,Ziyan WANG,Yu WANG,Lian WANG. Effect of pulmonary artery to aorta diameter ratio on prognosis in patients with acute decompensated heart failure [J]. The Journal of Practical Medicine, 2025, 41(7): 960-967.
[8]	Qiaoying MO,Fangyi ZHU,Cunkui ZHU,Shenglong. MA. Nomogram model of malnutrition risk in patients suffering from chronic heart failure grounded on GNRI score [J]. The Journal of Practical Medicine, 2025, 41(5): 691-698.
[9]	Guangyan WANG,Heng SU,Jun. ZHU. Effect of dagliflozin combined with levosimendan on sST2， Ang⁃Ⅱ and cardiac function in elderly patients with post⁃PCI heart failure [J]. The Journal of Practical Medicine, 2025, 41(3): 396-402.
[10]	Sihua DING,Xiaowen MOU,Xiuwei. WANG. Clinical effects of different courses of recombinant human brain natriuretic peptide on patients with heart failure due to acute ST‑segment elevation myocardial infarction [J]. The Journal of Practical Medicine, 2025, 41(23): 3753-3759.
[11]	Xin WU,Geqi DING,Lufeng LI,Tie HU,Fei. ZENG. Association of serum sST2， NT⁃proBNP and echocardiographic parameters with myocardial remodeling in patients with heart failure after acute myocardial infarction [J]. The Journal of Practical Medicine, 2025, 41(19): 3034-3040.
[12]	Yinglan HUANG,Fuwei LIU,Li XIAO,Jing WANG,Hongping HU,Jun LUO. Application of a mindfulness based self⁃care intervention program for chronic heart failure patients and their caregivers [J]. The Journal of Practical Medicine, 2025, 41(17): 2624-2630.
[13]	Yanru LI,Weidong JIN,Hao GUO,Minglei HAN,Zhen LIU,Yonglan HOU. Nomogram model of recurrence after RFCA for patients with atrial fibrillation complicated with heart failure [J]. The Journal of Practical Medicine, 2025, 41(17): 2637-2645.
[14]	Chunhong FAN,Wenlong HU,Limei ZHU,Ruifu YANG,Daxia CAI,Shaohua LU,Xingdong CAI. Synergistic diagnostic potential of novel biomarkers SYWC and ADA for tuberculous pleural effusion [J]. The Journal of Practical Medicine, 2025, 41(15): 2406-2411.
[15]	Su LIU,Tengfei JI,Dan LIU,Juanli ZHANG,Hong WEN,Li LI,Shuguang QIN. Efficacy of inspiratory muscle training combined with external diaphragm pacing in elderly patients with chronic heart failure [J]. The Journal of Practical Medicine, 2025, 41(13): 2011-2017.